CHEMBL308 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Cyclin-dependent kinase 1 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P06493. Start with chronic lymphocytic leukemia, then reuse UniProt P06493 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with chronic lymphocytic leukemia, then reuse UniProt P06493 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs

Open source guide

Disease program

chronic lymphocytic leukemia

Cyclin-dependent kinase 1 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include ALVOCIDIB, DINACICLIB, ZOTIRACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Late clinical Open Targets-ready proxy 3 linked drugs

Open disease block

Protein anchor

Cyclin-dependent kinase 1

Review this target as Cyclin-dependent kinase 1, mapped to UniProt P06493. Sequence length is 297 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P06493 Protein 297 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 1 as ChEMBL target CHEMBL308, mapped to UniProt P06493. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Cyclin-dependent kinase 1

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL308

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

P06493

Cyclin-dependent kinase 1

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 1 is the right protein anchor across sources, using UniProt P06493 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as late clinical support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Cyclin-dependent kinase 1
Target Type	SINGLE PROTEIN
Organism	Homo sapiens
UniProt	P06493

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Cyclin-dependent kinase 1
UniProt Accession	P06493
Component Type	Protein
Sequence Length	297 aa

Cyclin-dependent kinase 1

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 7:40 PM KST As of · Sep 14, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 1, mapped to UniProt P06493. Sequence length is 297 aa.

Mapped IDP06493

Review nameCyclin-dependent kinase 1

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Cyclin-dependent kinase 1 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III

chronic lymphocytic leukemia

3 linked drugs · 3 direct · 3 efficacy

Linked drugALVOCIDIB

Linked drugDINACICLIB

Linked drugZOTIRACICLIB

Clinical signal Phase II

acute myeloid leukemia